The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors.

Abstract

Liver metastasis represents a common systemic complication of colorectal cancers (CRCs). Partial liver resection has been demonstrated to result in long-term survival in certain well-selected patients with otherwise well-controlled systemic disease. Neoadjuvant therapy has been demonstrated to result in improved resectability and potentially longer survival in patients with liver metastases from CRC. The addition of biologic agents to chemotherapy has been shown to improve response rates and overall survival in patients with metastatic CRC. Here, we are discussing the role of biologic agents in the treatment of patients with liver metastases from CRC. We also discuss the role of biomarkers for response and resistance to such novel therapies.

• Authors: Harold J Wanebo, David Berz
• Journal: Journal of surgical oncology (J Surg Oncol) Vol. 102 Issue 8 Pg. 891-7 (Dec 15 2010) ISSN: 1096-9098 [Electronic] United States
• PMID: 21165990 (Publication Type: Journal Article, Review)
• Copyright: © 2010 Wiley-Liss, Inc.

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents
• ErbB Receptors

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Antineoplastic Agents (administration & dosage)
• Colorectal Neoplasms (drug therapy, pathology)
• Combined Modality Therapy
• ErbB Receptors (antagonists & inhibitors)
• Hepatectomy
• Humans
• Liver Neoplasms (drug therapy, secondary, therapy)
• Neoadjuvant Therapy
• Survival Analysis